MYMETICS CORP
Categories of dependency expected for this filer that were actually found stated in Risk Factors / MD&A.
- Filing
- 0001654954-23-004582 (10-K)
- Period
- 2022-01-01 to 2022-12-31
- XBRL tag
- us-gaap:Revenues
- Context
- From2022-01-01to2022-12-31
- Mapping
- seed · confidence 1.00
Extracted from Risk Factors / MD&A, checked verbatim against the source text before being stored.
“We require significant funding to maintain our current level of operations and continue to operate as a going concern.”
“Because we depend on third-parties to conduct some of our laboratory testing, future clinical trials, and our vaccine manufacturing, we may encounter delays in or lose some control over our efforts to develop and supply products.”
“Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.”
“There is significant competition in the development of a vaccine against COVID-19, influenza, and RSV and we may never see returns on the resources we are devoting to our vaccine candidates.”
“We have not completed the development of vaccine products and we may not succeed in obtaining the FDA licensure necessary to sell such vaccine products.”
“Even if regulatory approval is received for our vaccine candidates, the later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions, including withdrawal of the product from the market.”
“Our success depends on our ability to maintain the proprietary nature of our technology.”
“If we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete effectively in our markets.”